These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12766843)

  • 1. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.
    Gatti G; Castelli-Gattinara G; Cruciani M; Bernardi S; De Pascalis CR; Pontali E; Papa L; Miletich F; Bassetti D
    Clin Infect Dis; 2003 Jun; 36(11):1476-82. PubMed ID: 12766843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
    Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
    HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
    Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
    Justesen US; Hansen IM; Andersen AB; Klitgaard NA; Black FT; Gerstoft J; Mathiesen LR; Pedersen C
    HIV Med; 2005 Sep; 6(5):334-40. PubMed ID: 16156881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
    Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
    Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.
    Burger DM; Bergshoeff AS; De Groot R; Gibb D; Walker S; Tréluyer JM; Hoetelmans RM;
    J Pediatr; 2004 Sep; 145(3):403-5. PubMed ID: 15343199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplifying drug regimens.
    HIV Hotline; 1998 Mar; 8(1):11. PubMed ID: 11365353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
    Bergshoeff AS; Fraaij PL; van Rossum AM; Wolfs TF; Geelen SP; de Groot R; Burger DM
    Antivir Ther; 2003 Jun; 8(3):215-22. PubMed ID: 12924538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.
    Grub S; Delora P; Lüdin E; Duff F; Fletcher CV; Brundage RC; Kline MW; Calles NR; Schwarzwald H; Jorga K
    Clin Pharmacol Ther; 2002 Mar; 71(3):122-30. PubMed ID: 11907486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
    Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.
    Hirt D; Urien S; Jullien V; Firtion G; Rey E; Pons G; Blanche S; Treluyer JM
    Antimicrob Agents Chemother; 2006 Mar; 50(3):910-6. PubMed ID: 16495250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indinavir, nelfinavir -- twice a day?
    TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.
    Cruciani M; Gatti G; Vaccher E; Di Gennaro G; Cinelli R; Bassetti M; Tirelli U; Bassetti D
    J Antimicrob Chemother; 2005 Apr; 55(4):546-9. PubMed ID: 15728147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
    HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
    Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
    Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three times daily dosing.
    Schuster T; Linde R; Wintergerst U; Funk MB; Kurowski M; Kreuz W; Hofmann D
    AIDS; 2000 Jul; 14(10):1466-8. PubMed ID: 10930171
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
    Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
    BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.